-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
India moves closer to dengue vaccine as final trials underway
As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the world's first single-dose shots against the deadly mosquito-borne disease.
Dengue, which causes severe flu-like symptoms and debilitating body aches, has exploded globally, fuelled by rising temperatures and densely populated cities.
The World Health Organization (WHO) says that almost half the world's population is now at risk, with 100–400 million infections every year. India alone has recorded over one million cases and at least 1,500 deaths since 2021.
Hoping to stem the global epidemic, Panacea Biotec has begun final Phase III trials of its vaccine, DengiAll, which has been pursuing for nearly 15 years.
More than 10,000 volunteers across the country are enrolled in the study, overseen by the Indian Council of Medical Research, with the vaccine on track for rollout as early as next year if the trial results are favourable.
"We will try to get this vaccine out there as soon as possible," Syed Khalid Ali, chief scientific officer of Panacea, told AFP in New Delhi.
Doctor Ekta Gupta, professor of clinical virology at the Institute of Liver and Biliary Sciences in New Delhi, said dengue was now considered hyperendemic in India, with all four virus serotypes circulating simultaneously.
"This vaccine is very much needed right now to control the occurrence of these cases, or at least prevent the severity."
- Climate change -
Monsoon outbreaks regularly push Indian hospitals to their limits, crowding urban wards and leaving rural regions grappling with late diagnoses and poor access to care.
Higher temperatures and changing rainfall patterns create ideal conditions for Aedes mosquitoes -- the vectors of dengue -- to reproduce and spread the virus.
Children are particularly vulnerable to the more severe form, called dengue hemorrhagic fever, as they are more likely to suffer low platelet counts and shock.
Participants in Phase III trials, which started in 2024, were randomly assigned to receive either the vaccine or a placebo, with the results expected later this year.
Vaccines against all four dengue serotypes have long posed a scientific challenge. Immunity to one strain does not protect against others, and secondary infections can be more severe.
Most existing candidates require multiple doses.
If approved, DengiAll would become one of the world's first single-dose dengue vaccines, following Brazil's approval of a similar shot last year.
It would also be the first such vaccine available in India, where no dengue shot is currently licensed for public use.
"We will be the second (single-dose) vaccine to come out... But in India and several lower-middle-income countries, we will be the first ones to roll out the dengue vaccine," Ali said.
The candidate is based on a tetravalent strain originally developed by the US National Institutes of Health.
- 'Hope for future' -
Panacea is the most advanced of three Indian firms licensed to use the strain, having developed its own formulation and secured a process patent.
Inside the company's research labs, doctor Priyanka Priyadarsiny, head of biological R&D, said vaccine development involves several steps, from proof-of-concept studies to regulatory checks.
"We are extremely cautious about purity, safety and adverse effects," she said. "Only after meeting regulatory specifications can a product be considered safe for public use."
At present, the WHO recommends only one dengue vaccine, Qdenga, produced by Japan's Takeda for children aged six to 16 in high-transmission settings.
Qdenga, which requires two doses administered three months apart, is not currently available in India.
Ali said DengiAll could be given to people aged one to 60 and is expected to offer long-term protection.
In India, final approval would come from the Drug Controller General of India, while WHO prequalification would be required for large-scale international use.
Experts say a successful Indian-made vaccine could be key to affordability and mass rollout in lower-income countries.
Virologist and Oxford University fellow Shahid Jameel -- who is not connected with the trial warned dengue incidence could rise by 50–75 percent by 2050 under current climate change trends.
Still, he cautioned that only Phase III results would determine whether a candidate meets the criteria for a safe and effective dengue vaccine.
"Phase III testing and follow-up are needed to show if the above conditions are met," he told AFP.
"Only then can we have a useful dengue vaccine. It is still early days, but there is hope for the future."
P.A.Mendoza--AT